Blood Res.  2021 Apr;56(S1):S34-S38. 10.5045/br.2021.2020327.

Myelodysplastic syndrome with genetic predisposition

• Park M

• KMID: 2515296
• DOI: http://doi.org/10.5045/br.2021.2020327

Abstract

Myelodysplastic syndrome (MDS) refers to a heterogeneous group of clonal blood disorders characterized by ineffective hematopoiesis, cytopenia, dysplasia, and an increased risk of acute myeloid leukemia (AML). A growing number of inherited genetic loci that contribute to MDS/AML development are rapidly being identified. As genetic sequencing has become increasingly integrated into clinical practice, clearly defined syndromes have emerged, known as the MDS/AML predisposition syndrome. With more patients and families being identified with predisposing conditions, knowledge of the approach of evaluating and managing MDS with genetic predisposition is increasingly essential. This article reviews MDS with genetic predisposition and the practical aspects of management in patients with predisposition syndrome.

Keyword

Myelodysplastic syndrome; Genetic predisposition